Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)

Journal of Clinical Oncology

Volumn 22, Issue 6, 2004, Pages 1078-1086

  Greenberg, Peter L ^a   Lee, Sandra J ^a   Advani, Ranjana ^a   Tallman, Martin S ^a   Sikic, Branimir I ^a   Letendre, Louis ^a   Dugan, Kathleen ^a   Lum, Bert ^a   Chin, David L ^a   Dewald, Gordon ^a   Paietta, Elisabeth ^a   Bennett, John M ^a   Rowe, Jacob M ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; ETOPOSIDE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; VALSPODAR; ANTINEOPLASTIC AGENT; CYCLOSPORIN DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD TOXICITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DOSE RESPONSE; DRUG CLEARANCE; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; LIVER TOXICITY; MYELODYSPLASTIC SYNDROME; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ADOLESCENT; ADULT; AGED; DISEASE FREE SURVIVAL; FEMALE; GENE; GENETICS; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; SURVIVAL; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOSPORINS; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; GENES, MDR; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MITOXANTRONE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; SURVIVAL ANALYSIS; UNITED STATES;

EID: 1842457644     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.07.048     Document Type: Article

References (53)

1. Velu T, Delbusscher L, Stryckmans P: Daunorubicin in patients with relapsed and refractory acute non-lymphocytic leukemia previously treated with anthracycline. Am J Hematol 27:224-225, 1988
2. Lowenberg B, Downing J, Burnett A: Acute myeloid leukemia. N Engl J Med 341: 1051-1062, 1999
3. Lepelley P, Soenen V, Preudhomme C, et al: Expression of multi-drug resistance p-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia 8:998-1004, 1994
4. List AF: Multidrug resistance: Clinical relevance in acute leukemia. Oncology 7:23-28, 1993
5. Arceci R: Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81:2215-2222, 1993
6. Campos L, Guyotat D, Archimbauld E, et al: Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473-476, 1992
7. Marie J-P, Zittoun R, Sikic BI: Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity. Blood 78:586-592, 1991
8. Wood P, Burgess R, MacGregor A, et al: P-glycoprotein expression on acute myeloid leukaemia. Br J Haematol 87:509-514, 1994
9. Boekhorst PAW, de Leeuw K, Schoester M. et al: Predominance of functional multidrug resistance (MDR-1) phenotype in CD34 + acute myeloid leukemia cells. Blood 82:3157-3162, 1993
10. List A, Spier C, Cline A, et al: Expression of the multi-drug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol 78:28-34. 1991
11. Leith C, Kopecky K, Godwin J, et al: Acute myeloid leukemia in the elderly: Assessment of MDR-1 and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A SWOG study. Blood 89:3323-3329, 1997
12. Herweijor H, Sonneveld P, Baas F, et al: Expression of mdr1 and mdr3 multidrug resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 82:1133-1140, 1990
13. Nooter K, Sonneveld P, Oostrum R, et al: Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with stimulation of drug accumulation that can be restored by cyclosporin-A. Int J Cancer 45:263-268, 1990
14. Solary E, Caillot D, Chauffert B, et al: Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10:1730-1736, 1992
15. List AF, Spier C, Greer J, et al: Phase I/II trial of cyclosporin as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11:1652-1660, 1993
16. Tallman MS, Lee S, Sikic BI, et al: Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Pilot Study. Cancer 85:358-367, 1999
17. Advani R, Saba H, Rowe JM, et al: Treatment of refractory/relapsed AML with chemotherapy plus the multi-drug resistance modulator PSC833 (Valspodar). Blood 93:787-795, 1999
18. Twentyman P, Bleehen N: Resistance modification by PSC 833, a novel non-immunosuppressive cyclosporin. A. Eur J Cancer 27: 1639-1642, 1991
19. Boesh D, Gaveriaux C, Jachez B, et al: In vivo circumvention of P-glycoprotein-mediated multi drug resistance of tumor cells with SDZ PSC833. Cancer Res 51:4226-4233, 1991
20. Keller R, Altermatt H, Hooter K, et al: SDZ PSC 833, a non-immunosuppressive cyclosporine and its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 50:593-597, 1992
21. Boote D, Dennis P, Twentyman P: Phase I study of etoposide with SDZ PSC833 as a modulator of multi- drug resistance in patients with cancer. J Clin Oncol 14:610-618, 1996
22. Keller RP, Altermatt HJ, Donatsch P, et al: Pharmacologie interactions between the resistance modifying cyclosporine SDZ PSC833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 51:433-438, 1992
23. Fisher GA, Lum BL, Hausdorff J, et al: Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 32A: 1082-1088, 1996
24. Dorr R, Karanes C, Spier C, et al: Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol 19:1589-1599, 2001
25. Greenberg P, Cox C, Le Beau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-2088, 1997
26. Paietta E, Andersen J, Racevskis J, et al: Modulation of multidrug resistance in de novo adult acute myeloid leukemia: Blood Rev 9:47-52, 1995
27. Paietta E: Classical multi drug resistance in acute myeloid leukemia. Med Oncol 14:53-60, 1997
28. S. Karger: Neoplasia. In Mitelman F (ed), An international system for human cytogenetic nomenclature. Basel, Switzerland, 1995, p 78
29. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Study. Blood 96:4075-4083, 2000
30. Slordal L, Andersen A, Warren DJ: A sensitive and simple high-performance liquid chromatographic method for the determination of mitoxantrone in plasma. Ther Drug Monit 15: 328-333, 1993
31. Hu OY, Chang SP, Song YB, et al: Novel assay method for mitoxantrone in plasma, and its application in cancer patients. J Chromatogr 532:337-350, 1990
32. Andersen A, Warren DJ, Slordal L: A sensitive and simple high-performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma. Ther Drug Monit 15:455-161, 1993
33. Manouilov KK, McGuire TR, Gordon BG, et al: Assay for etoposide in human serum using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 707:342-346, 1998
34. Lum BL, Kaubisch S, Yahanda AM, et al: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635-1642, 1992
35. Beal SL, Sheiner LB: Methodology of population pharmacokinetics, in, Garrett ER, Hirtz J (eds), Drug Fate and Metabolism: Methods and Techniques, Vol 5, New York, NY, Marcel Decker, 1985, pp 135-183
36. Ludden TM: Population pharmacokinetics. J Clin Pharmacol 28:1059-1063, 1988
37. Attal M, Canal P, Schlaifer D, et al: Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. J Clin Oncol 12:141-148, 1994
38. Ciccolini J, Monjanel-Mouterde S, Bun SS, et al: Population pharmacokinetics of Etoposide: Application to therapeutic drug monitoring. Ther Drug Monit 24:709-714, 2002
39. Agresti, A: Categorical Data Analysis. New York, NY, Wiley, 1990, pp 59-66
40. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-461, 1958
41. Lehmann EL: Nonparametrics: Statistical methods based on ranks. Upper Saddle River, NJ, Prentice-Hall, 1993, pp 5-12
42. Pampallona S, Tsiatis AA: Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. Journal of Statistical Planning and Inference 42:19-35, 1994
43. Estey E, Kornblau S, Pierce S, et al: A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory AML. Blood 88:756, 1996
44. Sato H, Preisler H, Day R, et al: MDR1 transcripts levels as an indication of resistant disease in acute myelogenous leukemia. Br J Haematol 75:340-345, 1990
45. Schneider E, Cowan KH, Bader H, et al: Increased expression of the multidrug resistance associated protein gene in relapsed acute leukemia. Blood 85:186-193, 1995
46. Beck WT, Grogan TM, Willman CL, et al: Methods to detect P-glycoprotein associated with multidrug resistance in patients' tumors. Consensus recommendations. Cancer Res 56: 3010-3020, 1996
47. Baer M, George S, Dodge R, et al: Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: CALGB study 9720. Blood 100:1224-1232, 2002
48. Gruber A, Bjorkholm M, Brinch L, et al: A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia. Leuk Res 27:323-328, 2003
49. Wattel E, Solary E, Hecquet B, et al: Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: Results of a randomized study. Br J Haematol 102:1015-1024, 1998
50. Sikic BI: Pharmacologic approaches to reversing multidrug resistance. Semin Hemat 34: 40-47, 1997(suppl 5)
51. List AF: Non-P-glycoprotein drug export mechanisms of multidrug resistance. Semin Hemat 34:20-24, 1997 (suppl 5)
52. Leith CP, Kopecky KJ, Chen IM, et al: Frequency and clinical significance of expression of the multidrug resistance proteins MDR1, MRP1 and LRP in acute myeloid leukemia. A Southwest Oncology Group study. Blood 94: 1086-1099, 1999
53. Cripe L, Tallman MS, Karanes C, et al: A phase II trial of Zosuquidar (LY335979), a modulator of P-glycoprotein activity plus daunorubicin and high dose cytarabine in patients with newly diagnosed secondary acute myeloid leukemia (AML), refractory anemia with excess blasts in transformation or relapsed/refractory AML. Blood 98:595a, 2001 (suppl 1)